Abstract
Patients with treatment‐resistant bipolar depression and insulin resistance who received metformin over 26 weeks and experienced reversal of insulin resistance saw significant improvement in depressive symptoms compared with those not experiencing reversal, a placebo‐controlled trial has found. Significant improvement in depression scores in the group of metformin converters was apparent by week 6 of treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
